Background-Secondary prevention therapies are indicated for patients with coronary artery disease (CAD). However, patients with nonobstructive CAD may be less likely to receive these therapies compared with patients with obstructive CAD. Therefore, we compared rates of secondary prevention medication prescription between patients with nonobstructive and obstructive CAD. 
S econdary prevention therapies are indicated for patients with established coronary artery disease (CAD) and those at high risk for developing CAD to improve survival, reduce risk of future myocardial infarctions (MI), decrease the need for interventional procedures, and improve quality of life. 1 These strategies, including secondary prevention medications (eg, aspirin, statins, ␤-blockers, angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers [ARB]), have been codified into the 2006 American Heart Association/American College of Cardiology (AHA/ACC) Guidelines for Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease. 2 These guidelines reflect the current standard of care for patients with CAD.
Coronary angiography remains the criterion standard for the diagnosis of CAD and assessment of its severity. CAD severity is usually classified as obstructive or nonobstructive, depending on the presence or absence of flow-limiting atherosclerotic coronary plaques. Although this anatomic taxonomy assists in determining the role of these plaques in myocardial ischemia, it is less useful in predicting the future risk of plaque rupture and subsequent acute coronary syndrome. In fact, pathological and angiographic studies have demonstrated that a majority of MIs result from the rupture of nonobstructive coronary plaques. [3] [4] [5] [6] [7] [8] [9] Accordingly, indications for secondary prevention therapies are not contingent on the presence of obstructive or nonobstructive CAD at the time of coronary angiography. 1, 2, 10 However, the focus on obstructive CAD at the time of coronary angiography may inadvertently lead to suboptimal secondary prevention treatment for patients with nonobstructive CAD. Currently, little is known about secondary prevention treatment patterns among these patients.
To address this gap in knowledge, we used the National Cardiovascular Data Registry (NCDR) Cath-PCI registry to evaluate secondary prevention medication prescription among patients with CAD after coronary angiography as a function of the degree of CAD obstruction. Specifically, we compared rates of aspirin, statin, ␤-blocker, and ACEI/ARB prescription at hospital discharge between patients with nonobstructive CAD and obstructive CAD. We hypothesized that patients with nonobstructive CAD would have significantly lower rates of secondary prevention medication prescription compared with patients with obstructive CAD. Demonstration of differences in secondary prevention among these CAD patients could lead to interventions to improve the quality of CAD prevention care and improved patient outcomes.
WHAT IS KNOWN
• Secondary prevention therapies are indicated for patients with coronary artery disease (CAD), which is typically defined by the presence of obstructive coronary atherosclerotic plaques.
• However, patients with nonobstructive CAD may also benefit from secondary prevention therapies.
WHAT THE STUDY ADDS
• Patients with nonobstructive CAD were significantly less likely to receive secondary prevention medication prescription at hospital discharge, as compared with patients with obstructive CAD. • Similar gaps occurred among patients with nonobstructive CAD who had class I indications for secondary prevention medications.
• These findings highlight an opportunity to improve the quality of care for CAD patients with nonobstructive disease.
Methods

Data Collection
The NCDR Cath-PCI Registry, cosponsored by the ACC and Society for Coronary Angiography and Intervention, is a national registry of patients undergoing diagnostic cardiac catheterizations and/or percutaneous coronary intervention (PCI) in the United States. 11 Patient and procedural information are collected using a standardized set of data elements and definitions, systematic data entry and transmission procedures, and rigorous data quality assurance standards. Only institutions with submissions passing the inclusion/exclusion criteria for data completeness were included. Additionally, a national external audit program, conducted by the West Virginia Medical Institute and sponsored by the NCDR, reviews and verifies data from a random sample of sites. The complete definitions of all variables, along with audit and quality control procedures, were prospectively defined by a committee of the ACC and are available at the ACC website (https://www.ncdr.com/WebNCDR/DefaultCathPCI.aspx). Our study used data from Version 3.0 of the Cath-PCI Registry.
Study Population
We 
Data Definitions
Consistent with standard definitions of flow-limiting stenoses, 12, 13 nonobstructive CAD was defined as a coronary artery stenosis Ͼ20% but Ͻ50% in the left main coronary artery or Ͼ20% but Ͻ70% in any other coronary artery, as recorded in the catheterization report. Obstructive CAD was defined as any stenosis Ն50% in the left main coronary artery and/or Ն70% in any other coronary artery.
Patients with a history of PCI were classified as having either nonobstructive or obstructive CAD, depending on the degree of stenosis noted on the current catheterization (eg, in-stent restenosis Ͻ70% would be defined as nonobstructive). Patients with prior coronary artery bypass grafting, regardless of the degree of CAD noted on the index catheterization, were classified as having obstructive CAD. To determine whether a graded relationship between degree of CAD obstruction and rates of medication prescription existed, we further stratified CAD patients into mild (left main stenosis Յ20% and all other stenoses Ͼ20% but Յ50%) and moderate (left main stenosis Ͼ20% but Ͻ50% and/or any other stenosis Ͼ50% but Ͻ70%) disease, based on prior classifications of CAD severity. 12, 13 Prescription rates for aspirin, statin, ␤-blocker, and ACEI/ARB at hospital discharge were collected from the discharge reports. Patients with a documented contraindication or missing data for 1 or more of the medications were excluded only from the analysis or analyses that evaluated that particular medication or medications ( (Figure 1 ).
Statistical Analysis
After classifying patients by the presence of nonobstructive or obstructive CAD, we compared demographics, clinical history, in-hospital medications, admission presentation, in-hospital adverse outcomes, and hospital characteristics by patient group. Categorical variables were compared using the Pearson 2 test, and continuous variables were compared using Wilcoxon tests.
For our primary analysis, we used generalized estimating equation (GEE) models to compare prescription rates of each secondary prevention medication (aspirin, statin, ␤-blocker, and ACEI/ARB) between patients with nonobstructive and obstructive CAD. GEE models were used to adjust for the clustering of patients by medical center. On the basis of a priori clinical reasoning and prior studies, 14 -17 we then entered potential confounders of the relationship between coronary artery stenosis severity and secondary prevention medication prescription into our models. Selected factors included demographics (age, sex, race [white versus nonwhite], insurance payor [commercial, government, or other]); clinical history (body mass index, prior MI, prior PCI, prior coronary artery bypass grafting, prior congestive heart failure [CHF], ejection fraction, hypertension, diabetes, glomerular filtration rate [GFR], cerebrovascular disease, peripheral vascular disease, chronic lung disease, tobacco use, dyslipidemia); in-hospital medications (aspirin, clopidogrel, ␤-blocker, statin); admission presentation (symptoms, ACS on admission, CHF on admission, cardiogenic shock on admission); periprocedural adverse outcomes (MI, cardiogenic shock, CHF, cerebrovascular accident, bleeding, vascular complications); and hospital characteristics (hospital location, profit status, teaching/ nonteaching hospital, geographic region, and PCI volume). All of these confounders were entered into all of the models constructed for our analyses. Rates of missing data were Ͻ1% for all variables except ejection fraction (16%) and GFR (5.2%), Missing ejection fraction values were imputed to a group median value based on the presence of ST-elevation-MI (STEMI), CHF, cardiogenic shock, and prior MI. Missing GFR values were imputed to a group median value based on the presence of STEMI, sex, and renal failure. Variables used to assign groups for imputation were derived from the NCDR mortality models (currently under review; http://www.ncdr.com/WebNCDR/RESEARCH.ASPX).
To further support our primary findings, we also conducted several secondary analyses. First, to determine whether secondary prevention medication prescription was a function of increasing CAD obstruction (ie, a "dose-response relationship"), we stratified the nonobstructive CAD population into mildly and moderately nonobstructive CAD populations. We then conducted secondary analyses comparing prescription rates among mildly nonobstructive, moderately nonobstructive, and obstructive CAD patients.
Second, to determine whether differences in prescription rates were present among those patients with clear indications for each medication class, we restricted our cohort to those patients with class I guideline indications for each medication. 2, 18 For aspirin use, we examined all patients with an acute coronary syndrome (ACS) presentation and patients with prior CAD or a CAD risk equivalent (prior MI, prior revascularization, cerebrovascular disease, peripheral vascular disease, or diabetes); for statins, we examined those patients undergoing catheterization for unstable angina or non-STEMI (based on the fact that this population is the only population that has current guideline recommendations specifically for statins 18 ); for ␤-blockers, we examined those patients undergoing catheterization for ACS, with a history of MI, or with an ejection fraction Ͻ40%; for ACEI/ARB, we examined those patients with a history of diabetes, hypertension, chronic kidney disease (GFR Ͻ60 mL/min), or an ejection fraction Ͻ40%. Among these subgroups, we compared rates of secondary prevention medication prescription by nonobstructive and obstructive CAD.
Third, to determine whether differences in prescription rates were present among higher-risk CAD patients, we identified 2 patient subgroups at particularly high risk for adverse cardiac events: patients hospitalized with an ACS and patients with prior CAD or a CAD risk equivalent (prior MI, prior revascularization, cerebrovascular disease, peripheral vascular disease, or diabetes). 1 We added first-order interaction terms (ACS*CAD severity; prior CAD or CAD risk equivalent*CAD severity) into our primary model to test for effect modification among these subgroups and then stratified by these comorbidities to compare rates of secondary prevention medication prescription by nonobstructive and obstructive CAD. 
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For all secondary analyses, GEE models were used similar to the primary analysis. All analyses were conducted with SAS software version 9.1 (SAS Institute, Cary, NC). Institutional review board approval for the analyses of the Cath-PCI registry was obtained by the Duke Clinical Research Institute.
Results
Patient Characteristics
Of the 1 489 745 CAD patients in our study cohort, 237 167 (15.9%) had nonobstructive CAD and 1 252 578 (84.1%) had obstructive CAD. Patient characteristics are shown in Table  1 . In general, patients with nonobstructive CAD were more likely to be younger, female, nonwhite, have lower rates of prior cardiac and vascular disease, have no or atypical symptoms on admission, and have fewer in-hospital adverse outcomes as compared with those with obstructive CAD. In addition, nonobstructive CAD patients had lower rates of inpatient medication use (ASA, clopidogrel, ␤-blockers, and statins) than obstructive CAD patients. Higher rates of inpatient medication use were present among patients with ACS compared with patients without ACS, regardless of the presence of obstructive or nonobstructive CAD (Table 2) . Nonetheless, obstructive CAD patients with ACS had higher rates of medication use compared with nonobstructive CAD patients.
Rates of Secondary Prevention Medication Prescription Between Nonobstructive and Obstructive CAD Patients
Nonobstructive CAD patients had significantly lower rates of aspirin (72.7% versus 90.9%), statin (60.0% versus 80.3%), ␤-blocker (57.9% versus 79.4%), and ACEI/ARB (45.9% versus 58.6%; all probability values Ͻ0.0001) prescription at hospital discharge, as compared with obstructive CAD patients. After adjustment for demographic, clinical, inpatient, and hospital factors, nonobstructive CAD patients remained significantly less likely to receive prescriptions for all 4 medications, as compared with obstructive CAD patients (Figure 2 ).
Rates of Secondary Prevention Medication Prescription Between Mildly Nonobstructive, Moderately Nonobstructive, and Obstructive CAD Patients
Of the 237 167 patients with nonobstructive CAD, 181 837 (76.7%) had mildly nonobstructive CAD and 55 330 (23.3%) had moderately nonobstructive CAD. In unadjusted analysis, both mildly and moderately nonobstructive CAD patients had significantly lower rates of rates of aspirin, statin, ␤-blocker, and ACEI/ARB prescription, as compared with obstructive CAD patients (Figure 3 ; pairwise comparison probability values Ͻ0.0001). Furthermore, prescription rates decreased HMO indicates health maintenance organization; BMI, body mass index; CABG, coronary artery bypass grafting; EF, ejection fraction; CVD, cerebrovascular disease; PVD, peripheral vascular disease; ASA, aspirin; and CVA, cerebrovascular accident.
*Denominator for percentages is total CHF on admission.
in a stepwise fashion with decreasing severity of obstructive disease. Mildly nonobstructive CAD patients had, on average, between 3.3% and 7.2% lower rates of secondary prevention medication prescription than moderately nonobstructive CAD patients.
After adjustment for demographic, clinical, inpatient, and hospital factors, the interaction term for increasing CAD obstruction for all 4 secondary prevention medication classes was significant (probability value Ͻ0.0001), indicating that the likelihood of receiving medication prescriptions significantly increased with increasing levels of CAD severity in a dose-response relationship. Both mildly and moderately nonobstructive CAD patients remained significantly less likely to receive prescriptions for all 4 medications as compared with obstructive CAD patients ( Figure 2 ). Among these subgroups with class I indications, nonobstructive CAD patients had significantly lower unadjusted rates of aspirin (80.6% versus 92.9%), statin (64.9% versus 82.1%), ␤-blocker (66.0% versus 83.1%), and ACEI/ARB (49.6% versus 60.6%) prescription at discharge, as compared with obstructive CAD patients. After adjustment for demographic, clinical, inpatient, and hospital factors, nonobstructive CAD patients remained significantly less likely to receive prescriptions for all 4 medications as compared with obstructive CAD patients (Figure 4) .
Rates of Secondary Prevention Medication Prescription Among CAD Patients With Class I Indications
Rates of Secondary Prevention Medication Prescription Among CAD Patients With ACS
A total of 823 563 (55.3%) patients underwent cardiac catheterization in the setting of ACS. Of these, 79 094 (9.6%) had nonobstructive CAD and 744 469 (90.4%) had obstructive CAD. At hospital discharge, ACS patients with nonobstructive CAD had significantly lower rates of aspirin (78.6% versus 93.5%), statin (64.9% versus 83.4%), ␤-blocker (64.4% versus 84.4%), and ACEI/ARB (49.2% versus 62.1%, all probability values Ͻ0.0001) prescription as compared with obstructive CAD patients.
In multivariable models, the interaction term for ACS (ACS*CAD severity) for all 4 secondary prevention medication classes was significant (probability value Ͻ0.0001), indicating that ACS modified secondary prevention prescription rates between nonobstructive and obstructive CAD. ACS patients with nonobstructive CAD remained significantly less likely to receive prescriptions for all 4 medications as compared with obstructive CAD patients ( Figure 5 ).
Rates of Secondary Prevention Medication Prescription Among CAD Patients With Prior CAD or a CAD Equivalent
A total of 866 286 (58.2%) of patients in our study cohort had either prior CAD or a CAD risk equivalent. 2 Of these, 119 225 (13.8%) had nonobstructive CAD and 747 061 (86.2%) had obstructive CAD. At hospital discharge, nonobstructive CAD patients had significantly lower rates of aspirin (75.3% versus 90.4%), statin (65.8% versus 80.2%), ␤-blocker (62.8% versus 79.9%), and ACEI/ARB (52.9% versus 62.2%) prescription as compared with obstructive CAD patients.
After multivariable adjustment, the interaction term for prior CAD or a CAD risk equivalent (prior CAD or CAD risk equivalent*CAD severity) for all 4 secondary prevention medication classes was significant (probability value Ͻ0.0001), indicating that prior CAD or a CAD risk equivalent modified secondary prevention prescription rates between nonobstructive and obstructive CAD. Nonobstructive CAD patients remained significantly less likely to receive prescriptions for all 4 medications as compared with obstructive CAD patients ( Figure 6 ).
Discussion
In this large study of patients undergoing coronary angiography, we found that the presence of nonobstructive CAD was significantly and strongly associated with lower rates of secondary prevention medication prescription at hospital discharge compared with to patients with obstructive CAD. Prescription rates exhibited a dose-response relationship with CAD severity, with the lowest rates of medication prescription occurring in patients with mildly nonobstructive CAD, followed by those with moderately nonobstructive CAD, then those with obstructive CAD. Furthermore, higher-risk nonobstructive CAD patients with clear indications and proven benefits from these therapies-ie, those with class I indications for 1 or more secondary prevention medications, undergoing catheterization for ACS, or having prior CAD or a CAD risk equivalent-also had lower rates of medication prescription as compared with obstructive CAD patients. These findings provide, to our knowledge, the first description of secondary prevention medication prescription among nonobstructive CAD patients and demonstrate significant gaps in its provision.
Few studies have examined patients with nonobstructive CAD, and almost all of these have focused on ACS populations. 14 -17 For example, Roe et al 17 demonstrated that nonobstructive CAD patients had a combined death and reinfarction rate of 6.0% 30 days after NSTEMI. Similarly, Bugiardini et al 15 demonstrated that nonobstructive CAD patients had a combined death and reinfarction rate of 2.1% 1 year after non-STEMI, based on pooled data from the TIMI-11B, 16, and 22 trials. These studies indicate rates of adverse events among nonobstructive CAD patients after ACS, though not as high as those with obstructive CAD, are not clinically insignificant. However, these studies did not evaluate secondary prevention medication use among the nonobstructive CAD patient population. Our study, by examining a large, national population of nonobstructive CAD patients, provides the most comprehensive assessment to date of the treatment patterns in this population and demonstrates both substantial gaps and potential opportunities in optimizing their cardiac care.
By characterizing gaps in secondary prevention medication prescription among nonobstructive CAD patients, our study identifies important targets for immediate improvement and suggests future directions for research. First, among those nonobstructive CAD patients with class I indications for secondary prevention medications, ACS, or prior CAD/CAD risk equivalents, aspirin, statins, ␤-blockers, and ACEI/ARBs have been shown to significantly reduce cardiac events. 2, 19 Interventions to optimize secondary prevention medication prescription at hospital discharge, such as discharge "checklists" or other systematic prescription programs, may help close this gap. In addition, these interventions may also need to focus on inpatient medication provision for patients with nonobstructive CAD, given that we also demonstrated gaps in their use compared with obstructive CAD patients. Second, a reevaluation of providers' approach to secondary prevention Figure 5 . Adjusted ODDS RATIOS with 95% confidence intervals of receipt of secondary prevention medication prescription at hospital discharge between nonobstructive (nϭ79 094) and obstructive (nϭ1 252 578) CAD patients with ACS. Figure 6 . Adjusted odds ratios with 95% confidence intervals of receipt of secondary prevention medication prescription at hospital discharge among nonobstructive (nϭ142 119) and obstructive (nϭ1 252 578) CAD patients with prior CAD or a CAD risk equivalent.
provision among patients with nonobstructive CAD may be necessary. In some cases, the message communicated from the catheterization laboratory to primary care providers and patients may be that the lack of obstructive CAD indicates "no significant disease," which may inadvertently imply that preventive therapies are unnecessary. If this message then leads to reduced rates of secondary prevention therapies, especially among those with a clear indication for its use, then improvements in communication of a patient's global cardiac risk and the role for appropriate secondary prevention treatments are necessary. Therefore, research into the role of communication among providers and patients on subsequent secondary prevention practices is needed. Finally, there are no current studies exploring the effect of secondary prevention medications on outcomes among nonobstructive CAD patients without class I indications for these therapies. The presence of atherosclerosis, regardless of its degree of obstruction, represents developing coronary disease and may confer significant risk for cardiac events for nonobstructive CAD patients over longer periods of time. Accordingly, institution of aggressive risk factor modification and other preventive therapies among these patients may significantly moderate this risk over time. This hypothesis has not been directly explored, and studies are needed to quantify potential benefits that these medications may have for patients with nonobstructive CAD.
Our analysis has several potential limitations. First, participation in the Cath-PCI registry of the NCDR is voluntary. However, our study cohort is composed of patients from 786 facilities throughout the United States, and there is no a priori reason to assume that care for nonobstructive CAD versus obstructive CAD patients would be different at hospitals that do not participate in NCDR. Second, obstructive and nonobstructive coronary disease was not verified by a core angiographic laboratory or other standardized methods of lesion assessment, such as quantitative coronary angiography. Accordingly, the potential for misclassification exists. However, the graded relationship demonstrated between CAD severity and medication prescription argues against significant misclassification. Furthermore, we have no reason to expect misclassification to be differential, suggesting that any bias would move our findings toward the null hypothesis. Third, incomplete documentation of contraindication to secondary prevention medications could also lead to misclassification. However, this misclassification probably would be nondifferential and again bias our results toward the null. Fourth, approximately 10% of patients were excluded from our study cohort because of missing discharge medication data, which could have introduced bias into our findings. However, the rates of nonobstructive CAD in these excluded patients was higher than in our study cohort (56% versus 16%), so we would expect that inclusion of these patients in our cohort would, if anything, accentuate the gaps in prescription between nonobstructive and obstructive CAD patients. Fifth, debate exists about optimal secondary prevention therapies for diabetic patients without prior CAD. However, because only 3497 (1.5%) of nonobstructive CAD patients in our cohort met this criteria, we would not expect it to materially affect our findings. Sixth, the NCDR cannot provide insight into postdischarge actions, such as prescription of secondary prevention medications during a subsequent outpatient visit. However, prior studies have demonstrated that if secondary prevention medications are not started during the hospitalization period, then they are less likely to be started in the outpatient period. 20, 21 Nonetheless, this study cannot directly measure whether these gaps in medication prescription persist after hospital discharge. Finally, the observed relationship between CAD severity and secondary prevention medication prescription may be confounded by unmeasured variables. This is a limitation of all observational studies. However, by adjusting for a large number of measured variables available through the NCDR registry, we believe that we can account for a significant amount of potential confounding.
In conclusion, this study found that the presence of nonobstructive CAD, in comparison to obstructive CAD, was significantly and strongly associated with lower rates of secondary prevention medication prescription at hospital discharge, both in the overall cohort as well as specified higher-risk CAD subgroups. These findings highlight both significant gaps and potential opportunities to improve the quality of care and outcomes for patients with nonobstructive CAD. 
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